Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
Market capitalisation
$4.13B
41,780,136 shares Covers every share class this company has on file.
Insiders on file
6
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$404.54M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
9.78%
insider-held value divided by market capitalisation
What Veradermics, Inc reports
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Revenue
—
No revenue figure: this company’s filings tag profit, but no single revenue total.
Net income
-$70.00M
FY2025a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
37
Yahoo Finance
Why the revenue box is blanki
US GAAP has no one “total revenue” tag that every filer uses. A bank reports interest and dividend income separately from non-interest income; closed-end funds, blank-cheque companies and some property trusts report the same way; and a company that has not sold anything yet — a drug developer still in trials, for instance — files no revenue at all. Adding two differently defined income lines together would produce a number that appears in no filing, so we publish a revenue figure only where the filing tags one annual, US-dollar revenue fact we can point at. A blank here means no such tag, not that we failed to look.
Where the employee count comes fromi
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Insiders at Veradermics, Inc
Shares is what each person last reported holding here.i
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
Rows are grouped by the role each person reports.i
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
People who file insider reports against Veradermics, Inc.
Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.
Aaron Cowen sold 750,000 Veradermics, Inc (MANE) shares for $80,437,500 on Aug 19, 2026
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Aaron Cowen sold 750,000 Veradermics, Inc (MANE) shares for $80,437,500 on Aug 19, 2026
Total of the rows above: $80,437,500, in the currency the filings report.
Summary written by an AI model from the filing data above (model: gemini-3.7-flash):
Aaron Cowen sold 750,000 shares of Veradermics, Inc through open-market sale transactions on 2026-08-19 for a total of $80,437,500.
The transactions included 690,601 shares sold at $107.25 per share for $74,066,957, leaving 2,957,937 shares held. An additional open-market sale of 59,399 shares was executed at $107.25 per share for $6,370,543, leaving 461,033 shares held.
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
4 insiders bought Veradermics, Inc (MANE) shares worth $34,817,458 between Feb 4, 2026 and Feb 6, 2026
Cluster buying
4 different insiders made 23 open-market purchases of this company’s shares within a short window. Each row below is one reported trade.
4 insiders bought Veradermics, Inc (MANE) shares worth $34,817,458 between Feb 4, 2026 and Feb 6, 2026
Total of the rows above: $34,817,458, in the currency the filings report.
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Patrick G. Enright bought 1,075,000 Veradermics, Inc (MANE) shares for $18,275,000 on Feb 5, 2026
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Patrick G. Enright bought 1,075,000 Veradermics, Inc (MANE) shares for $18,275,000 on Feb 5, 2026
Total of the rows above: $18,275,000, in the currency the filings report.
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Aaron Cowen bought 53,344 Veradermics, Inc (MANE) shares for $1,979,596 on Feb 4, 2026
Large trade for this person
Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.
Aaron Cowen bought 53,344 Veradermics, Inc (MANE) shares for $1,979,596 on Feb 4, 2026
Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.
Recent insider transactions
Of the 54 rows we hold,
23 are open-market
purchases (P) and
15 open-market
sales (S) — the only codes we count as buying or selling.i
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
Insider transactions disclosed to the SEC for Veradermics, Inc, newest first, each with the filing behind it.
From SEC Form 4 filings. Every row links to the filing it
came from. How we calculate this.
What a Form 4 isi
The report an officer, director or large shareholder must file after trading their own company’s stock.
Corporate ownership links — 7 filers hold a position
Who owns Veradermics, Inc
Each row is one filer naming this company.i
Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.
Do not add these figures together.
7 of the positions below were reported on filings shared by several filers at once.
Why the same shares appear twicei
On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.
Filers holding a position in Veradermics, Inc
Funds, trusts and companies that disclose an ownership
position in Veradermics, Inc.
Think a number here is wrong?
Open the linked filing and compare —
how to report it.
Sources and technical notes
Every figure on this page comes from filings to the U.S. SEC via EDGAR.
Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
Veradermics, Inc’s own filings and multiplied by our closing price.
Full method.
What that share count meansi
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure
is a share count from Veradermics, Inc’s
own SEC filings multiplied by
the closing price we hold for the same stock.
